StockNews.AISignal intelligence
Abbott Laboratories · NYSE · Healthcare
Browse public ABT signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Abbott reports Q3 earnings on Oct 21 before the open, with consensus $1.41 per share on $12.99 billion revenue. The Oct 5 FDA approval for CardioMEMS HF System updates, including the CardioGuide HF App, could lift the device portfolio and drive growth expectations. With bullish analyst sentiment and higher price targets, ABT may rally on a stronger-than-expected print and regulatory upside.
View signal analysisBarclays initiated Abbott Laboratories (ABT) with an Overweight rating and a $120 target, signaling confidence in continued growth. ABT trades around $98.16, implying roughly 22% upside to the target. This move comes amid a broader wave of analyst initiations, potentially bolstering near-term upside for ABT shares.
View signal analysisRothschild & Co boosted Abbott Laboratories' price target from 119 to 127 and upgraded the stock to Buy, signaling renewed confidence in ABT's fundamentals. The move follows no stated earnings change in the article, but the target lift suggests potential near-term upside as analysts recalibrate valuation. With ABT trading around mid- to high-90s, the upgrade could spur a short-term rebound.
View signal analysisAbbott Laboratories agreed to pay more than $384 million to settle DOJ allegations tied to contaminated infant formula. The settlement resolves the lawsuit but signals ongoing regulatory risk in ABT's consumer healthcare operations. The charge is non-recurring and, while modest relative to ABT's scale, could weigh on near-term earnings.
View signal analysisAbbott is FDA De Novo authorized to launch Libre Duo 10 Day, the first dual glucose–ketone biowearable. It monitors glucose and rising ketones in the background, with a US launch planned later this year. The device aims for broad AID pump integrations through 2027, expanding Libre's diabetes ecosystem.
View signal analysisAbbott announced settlements with three law firms to resolve the Gill case and NEC claims for about 12,700 infants across roughly 1,700 lawsuits, totaling about $670 million. The agreements are non-admissions of liability and follow favorable MDL outcomes. This reduces litigation tail risk and could support modest near-term upside for ABT, though core fundamentals remain unchanged.
View signal analysis